Vectus Biosystems Limited (ASX:VBS)

Market Cap	6.76M -51.1%
Revenue (ttm)	89.96K -89.8%
Net Income	-1.41M
EPS	-0.03
Shares Out	61.49M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	203,942
Open	0.1000
Previous Close	0.1050
Day's Range	0.1000 - 0.1100
52-Week Range	0.0370 - 0.4550
Beta	0.22
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 3, 2026

About Vectus Biosystems

Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for cardiovascular fibrosis and systolic blood pressure, as well as treatments for cardiac fibrosis, kidney, liver, and lung fibrosis. Its lead compound is VB0004, currently under phase Ib clinical human trial, which is aimed at treating the loss of functional tissue to fibrosis, and scarring. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohe...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: VBS

Financial Performance

In fiscal year 2025, Vectus Biosystems's revenue was 478,182, a decrease of -58.01% compared to the previous year's 1.14 million. Losses were -1.78 million, -23.99% less than in 2024.